Ultragenyx Pharma (RARE) Misses Q4 EPS by 2c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($2.16), $0.02 worse than the analyst estimate of ($2.14). Revenue for the quarter came in at $103.35 million versus the consensus estimate of $101.94 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• J.B. Hunt Transport Services (JBHT) PT Raised to $261 at Stifel Into Q2 Earnings
• Macquarie cuts Macau gaming sector forecasts on weak GGR growth